Outcomes following biosimilar TNF inhibitor use for inflammatory-mediated immune disorders in pregnancy

BACKGROUND: Biosimilar tumour necrosis factor inhibitors (TNFi) are increasingly used to treat inflammatory immune-mediated disorders as they cost less than the originator biologic drug. More women are therefore becoming pregnant on biosimilar TNFi. This is the first paper to explore the safety and...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, R, Parker, H, Mccartney, S, Harrow, P, Williams, D, Giles, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277732/
https://www.ncbi.nlm.nih.gov/pubmed/35845229
http://dx.doi.org/10.1177/1753495X211028779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277732/
https://www.ncbi.nlm.nih.gov/pubmed/35845229
http://dx.doi.org/10.1177/1753495X211028779

Ejemplares similares